 PITTSBURGH, April 27, 2021 GLOBE NEWSWIRE -- Krystal Biotech Inc., Krystal NASDAQ: KRYS, the leader in redosable gene therapies for rare diseases, today announced that it will present preclinical data from its vector-encoded-antibody platform in a digital poster presentation at the upcoming American Society of Genetic Cell Therapy ASGCT Annual Meeting held virtually May 11-14, 2021. Data to be presented includes evidence of in vitro molecular efficacy with KB501 expressing a TNF-α targeting antibody, and in vivo proof-of-concept in two models of atopic dermatitis with KB501 and KB502 expressing an IL-4Rα targeting antibody. 